Félix Jaminion

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer

Peter N. Morcos, E. Nueesch, Félix Jaminion et al. · Cancer Chemotherapy and Pharmacology · 2018 · 28 citations · Full text

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Nassim Djebli, Peter N. Morcos, Félix Jaminion et al. · Blood · 2020 · 16 citations

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase<i>–</i>positive non‐small cell lung cancer

Joy Hsu, Félix Jaminion, Elena Guerini et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 14 citations · Full text